European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

Contributed by: Business Wire

Logo

Tags

Biotechnology

General Health

Neurology

Health

Pharmaceutical

DAYBU, trofinetide

More Like This

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

Leqembi® (lecanemab) launched in the EU today

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

First patient treated with Leqembi® (lecanemab) in the Nordics

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)